Article
Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2015
Kreimer Aimée R, Brennan Paul, Lang Kuhs Krystle A, Waterboer Tim, Clifford Gary, Franceschi Silvia, Michel Angelika, Willhauck-Fleckenstein Martina, Riboli Elio, Castellsagué Xavier, Hildesheim Allan, Fortner Renée Turzanski, Kaaks Rudolf, Palli Domenico, Ljuslinder Ingrid, Panico Salvatore, Clavel-Chapelon Françoise, Boutron-Ruault Marie-Christine, Mesrine Sylvie, Trichopoulou Antonia, Lagiou Pagona, Trichopoulos Dimitrios, Peeters Petra H, Cross Amanda J, Bueno-de-Mesquita H Bas, Vineis Paolo, Larrañaga Nerea, Pala Valeria, Sánchez María-José, Navarro Carmen, Barricarte Aurelio, Tumino Rosario, Khaw Kay-Tee, Wareham Nicholas, Boeing Heiner, Steffen Annika, Travis Ruth C, Quirós J Ramón, Weiderpass Elisabete, Pawlita Michael, Johansson Mattias
Abstract excerpt
PURPOSE: Human papillomavirus (HPV) type 16 (HPV16) causes cancer at several anatomic sites. In the European Prospective Investigation Into Cancer and Nutrition study, HPV16 E6 seropositivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in controls. The current study sought to evaluate the extent to which HPV16 E6 antibodies are present before diagnosis of anogenital...
Read the complete abstract on PubMed